Osteoporosis and diseases of bone loss are a major public health problem for the present and the future since longevity and prevalence of the disease are increasing in all parts of the world. The bisphosphonates, widely used in the treatment of osteoporosis, act by inhibiting bone resorption. However, there are few agents that promote or increase bone formation in patients who have suffered substantial bone loss. To facilitate the identification of novel anabolic therapies, the authors have developed a rapid, high-throughput in vivo screen using larval zebrafish (Danio rerio) in which they are able to identify agents with anabolic effects in the skeleton within a 6-day time period. Vitamin D 3 analogs and intermittent parathyroid hormone (PTH) result in dose-dependent increases in the formation of mineralized bone, whereas continuous exposure to PTH results in net bone loss. Because this model is fast, economical, and genetically tractable, it provides a powerful adjunct to mammalian models for the identification of new anabolic bone agents and offers the potential for genetic elucidation of pathways important in osteoblastic activity. (Journal of Biomolecular Screening 2005:823-831) 
INTRODUCTION
O STEOPOROSIS AND OTHER DISEASES of bone loss represent a major public health problem, with an estimated 100 million people at risk of developing the disease worldwide. 1, 2 Osteoporosis is characterized by a gradual reduction in bone mass to a point where the skeleton is compromised, leading to bone fragility and susceptibility to fractures. Although a number of effective therapies exist that decrease bone resorption and stabilize bone mass, there are fewer, if any, therapies that are proven to be effective in increasing bone mass and improving the defects in bone microarchitecture characteristic in established and advanced osteoporosis or for accelerating fracture healing. Here we assess whether zebrafish have a role to play in addressing this problem.
Zebrafish are becoming popular to model several human disease states because of their scalability and potential vertebrate relevance. 3 Currently, disease models have been created across a range of different therapeutic areas, including ophthalmology, neurology, hematology, cardiovascular disease, and cancer. 4 Zebrafish are an established system for investigating developmental aspects of bone formation 5-8 but hitherto have not been used for clinically directed endpoints. In addition, the zebrafish genome has been sequenced and shown to contain a similar number of genes compared to the human genome, with high homology across key protein binding domains, in many cases. 3 For these reasons, we assessed whether zebrafish models could prove useful to screen for novel anabolic bone compounds.
Studies of bone development, growth, and remodeling in teleosts, particularly zebrafish, have been increasingly studied over the past 10 years. [9] [10] [11] [12] [13] [14] The aim of this study was to establish whether zebrafish could be used to identify targets and compounds that lead to anabolic effects and, moreover, could be used to dissect out the differential nature of a compound's efficacy on osteoblast differentiation and function. Because zebrafish develop so rapidly, assays were configured in which the fish are 3 to 4 mm in length and can live in as little as 50 µL of fluid, making 96-well plate format assays possible. In this feasibility assessment, we evaluated vitamin D 3 analogs, PTH, a selection of HMG-CoA reductase inhibitors (statins), and the bisphosphonate, etidronate.
MATERIALS AND METHODS

Husbandry
Embryos were collected from matings of adults (TL strain) and reared under standard conditions. 15 Embryos were reared in embryo medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl 2 , 0.33 mM Mg 2 SO 4 , 10 -5 % Methylene Blue) and staged using standard criteria. 16 
High-throughput screening in 96-well plates
Larvae at 3 days postfertilization (dpf) were transferred into 96well plates (Millipore) containing embryo medium. Compound screening was performed in 96-well plates with 3 fish per well (hereafter called the screening plate). The final volume of embryo medium per well was adjusted to 200 µL. Master plates of test compounds were made at 100× test concentration in 96-well plates. Then, 2 µL of compound from the master plate was added to each well of the screening plate using a multichannel pipette. Duplicate or triplicate wells were set up for each compound at each concentration. Negative controls and appropriate vehicle controls (DMSO and ethanol) were included in each test plate. The concentration of vehicle was equivalent to that added to the drug treatment wells. Screening plates were sealed and incubated in the aquarium (28.5°C) until 9 dpf, at which point larvae were anesthetized and fixed for skeletal staining as described.
Vitamin D 3 , 1 , 25-dihydroxyvitamin D 3 , and etidronate
Larvae (n = 6 per treatment group) were reared from 3 to 9 dpf in compounds with predicted bone efficacy, then processed for skeletal staining as described. A 100-mg/mL stock of vitamin D 3 (cholecalciferol) (Sigma C9774) was made in DMSO, and smallvolume aliquots were stored at -20°C. A 5-mg/mL stock of 1α, 25-dihydroxyvitamin D 3 (calcitriol) (Sigma D1530) was made in ethanol, and small-volume aliquots were stored at -20°C. All compounds were tested at a range of concentrations (vitamin D 3 from 10 ng/mL to 1 µg/mL; calcitriol from 1 fg/mL to 1 ng/mL) to find the most effective anabolic dose. Etidronate (Sigma) was used as an antiresorptive comparator in the vitamin D 3 assays. Etidronate was used at a final concentration of 10 µg/mL in embryo medium.
Effects of continuous and intermittent parathyroid hormone exposure on bone mineralization
A 1-mg/mL stock of teriparatide (rhPTH (1-34), Lilly) was made in 20 mM NaH 2 PO 4 , 0.9% NaCl, and 2.13 g/L mannitol. A range of doses, from 1 to 100 ng/mL, was tested in larvae from 3 to 9 dpf, with n = 9 larvae per treatment group. Larvae were either exposed continuously to the same dose of parathyroid hormone (PTH) throughout the assay or intermittently exposed for 2 h every other day. At 9 dpf, larvae were anesthetized, fixed in 4% paraformaldehyde, and processed for skeletal staining as described.
Effects of statins on bone mineralization
A panel of statins (atorvastatin, pravastatin, and simvastatin) was tested to investigate whether bone anabolic effects could be detected. A 1-mg/mL stock of each statin was made in dH 2 O. The statins were tested at a range of concentrations (atorvastatin [Goedecke AG] at 10 ng/mL to 20 µg/mL; pravastatin [Bristol-Meyers Squibb] at 200 ng/mL to 100 µg/mL; simvastatin [Merck Sharp & Dohme Ltd] at 5 ng/mL to 100 µg/mL) to find the most effective, nontoxic dose, with n = 6 larvae per treatment group. At 9 dpf, larvae were fixed and processed for whole-mount skeletal staining.
Skeletal staining
Embryos and larvae were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS), then labeled with alizarin red as described previously. 17 All staining was performed in 96-well mesh plates (Millipore).
Quantification of bone mineralization
The ventral aspect of the head skeleton of alizarin red-stained larvae was visualized using a SZX12 stereomicroscope (Olympus), and images were captured using a ColorView camera (Olympus) and AnalySis software (Soft Imaging System). For each test plate, all images were taken in a single session, with identical lighting and exposure settings. The area of alizarin red staining was quantified for each treatment group, with a minimum of 6 samples per group, using color threshold and area measurements in Analy-Sis. For each test plate, the hue, saturation, and intensity levels were set at a threshold to include all areas stained with alizarin red in the control (vehicle-treated) group, and the area within this threshold was calculated. The same threshold settings were thereafter applied to all images of larvae from the same plate. Exclusion of the otoliths and integrated optical density (IOD) measurements were performed using ImagePro (Media Cybernetics, San Diego, CA). Hue, saturation, and intensity levels were set at a threshold to include all areas stained with alizarin red in the control (vehicletreated) group, and the density of staining within this area was calculated. The same threshold settings were thereafter applied to all images of larvae from the same plate. Mean values, standard deviations, and t-tests were calculated using Excel software (Microsoft Office).
Reproducibility of quantification
Following skeletal staining as described, a single larva was transferred into a Petri dish and visualized using a SZX12 stereomicroscope, and an image was captured using a ColorView camera and AnalySis software. The larva was removed and transferred to a new dish, repositioned, and captured in a 2nd image. This was repeated 5 times. The area of alizarin red staining was quantified for each image using color threshold and area measurements in AnalySis. Mean and standard deviation were calculated in Excel. The coefficient of variance was calculated for this set of images using the following formula:
Coefficient of variance = (standard deviation ÷ mean) × 100.
RESULTS
Vitamin D 3 analogs increase mineralized matrix in larval zebrafish
We observed that skeletal effects of vitamin D 3 analogs could be detected in whole-mount skeletal preparations after as little as 6 days of exposure. Treatment with vitamin D 3 at 10 and 50 ng/mL ( Fig. 1B) caused an apparent increase in the staining intensity and pixel number, which corresponds to the stained area (mineralized area), and was compared to vehicle-treated controls ( Fig. 1A) . Using digital image analysis, the mineralized area was quantified for each sample in each treatment group. A clear dose-response rela-tionship was observed with increasing doses of vitamin D 3 enhancing the mineralized area (Fig. 1C ). Statistically significant increases in the mineralized matrix were observed at 10 and 50 ng/ mL (Student t-test, p < 0.05) relative to vehicle controls. An increase in mineralized area was also observed following etidronate treatment, but the increase in mineralization observed with 50 ng/ mL vitamin D 3 was greater than that observed with etidronate. In data not shown, etidronate did not further increase the mineralized matrix at higher doses. The increase in the mineralized area following etidronate treatment was somewhat unexpected because this was included as an antiresorptive comparator. However, it has previously been shown that bisphosphonates prevent bone resorp- tion without affecting longitudinal bone growth (modeling), resulting in club-shaped bones and increased bone mass in rats. 18 Dose-response studies performed with 1α, 25dihydroxyvitamin D 3 showed skeletal efficacy similar to vitamin D 3 but at lower doses ( Fig. 1D ). Repeated dose-response studies were performed to identify the lowest concentration capable of producing anabolic bone effects. Testing within a narrow dose range revealed a linear dose response from 10 to 100 fg/mL. Above this dose, the anabolic effect reached a plateau, with the maximal effect comparable to that observed with 50 ng/mL vitamin D 3 (Fig.  1D ). Statistically significant increases in bone were seen with as little as 25 fg/mL 1α, 25-dihydroxyvitamin D 3 (Student t-test, p < 0.05), relative to vehicle controls.
High-Throughput Screening for Bone Anabolic Therapies
Intermittent PTH exposure has anabolic skeletal efficacy, whereas catabolism is observed with continuous PTH exposure
Skeletal effects of intermittent and continuous teriparatide (PTH) were next evaluated. Viability of zebrafish was unaffected by the continuous presence of the highest dose of PTH (100 ng/ mL) evaluated. Larval length was used to determine whether PTH treatment had effects on longitudinal skeletal growth because this is a known consequence of PTH administration in rats, another species that continues to grow throughout most of its life span. PTH had no effect on the length of zebrafish, whether administered intermittently or continuously (Table 1) . When compared to untreated controls ( Fig. 2A) , intermittent PTH exposure at 30 ng/mL produced a marked increase in the alizarin red staining of zebrafish ( Fig. 2B) . Image analysis demonstrated a statistically significant increase in mineralized area at 10 and 30 ng/mL (Student t-test, p < 0.05) of 15.8% and 16.6%, respectively (Fig. 2C) . Digitized images permitted measurement of the area under the thresholded pixel distribution (IOD), as a surrogate measure for bone mineral content. The otoliths were excluded from this analysis because they are composed of calcium carbonate rather than bone and appeared less affected by PTH treatment on visual inspection. IOD analysis revealed a nonsignificant anabolic effect at doses of 10 and 30 ng/mL (Student t-test, p > 0.05), with an increase in the IOD of 8.1% and 5.7% with 10 ng/mL and 30 ng/mL, respectively (Fig.  2D) . By contrast, continuous exposure to all doses of PTH resulted in a striking decrease in mineralized bone after 6 days of treatment ( Fig. 3B ) when compared to controls (Fig. 3A) . Image analysis of mineralized area revealed only a statistically significant loss of bone at 30 ng/mL PTH (Fig. 3C) , whereas IOD analysis revealed a significant dose-dependent reduction in mineralization at all doses tested (Student t-test, p < 0.01). The reduction in IOD ranged between 69% and 83% below that of control levels, across the dose range (Fig. 3D) . These data show that PTH has effects on the larval zebrafish skeleton, not unlike the anabolic and catabolic skeletal effects described previously for continuous and intermittent PTH treatment in rat models. 19, 20 Furthermore, different methods of image analysis demonstrated that although anabolic effects are most readily quantified using mineralized area measurements, bone loss is more effectively measured using measurements of optical density because it is the intensity of staining, hence bone density, that is reduced rather than bone area.
Statins showed no detectable bone anabolic effects in zebrafish
A wide range of doses of a panel of statins was explored for effects on bone tissue. Toxic doses were established for each of the compounds tested, demonstrating that compounds were tested at sufficiently high doses. Atorvastatin was toxic above 5 µg/mL, pravastatin was toxic at 100 µg/mL, and simvastatin was toxic at 100 ng/mL. No obvious bone effects were observed by visual inspection of stained larvae for the tolerated doses used for atorvastatin, pravastatin, or simvastatin. Image analysis showed no significant difference in mineralization between control and treated groups at any of the doses tested ( Fig. 4 ).
Variation in measurement techniques
A single fish was taken and imaged once, removed from the Petri dish used for photography, and replaced in a separate dish and imaged again. This was repeated 5 times for the same sample. The mineralized area in each image was calculated, and a mean value and standard deviation were calculated to determine the amount of variance that occurs in this imaging technique. The mean area calculated was 24670.54 µm 2 with a coefficient of variation of 3.64%.
DISCUSSION
Zebrafish skeletal physiology may resemble rodent bones
Zebrafish bones resemble mammalian bones, with both intramembranous and endochondral ossification being seen in the craniofacial skeleton. 7, 10 The bones are vascularized, innervated, and contain cavities filled with adipose tissue. 21 The exact shape and form that the bone takes reflect their aqueous environment, with the macroarchitecture being dependent on its function. Bottom-dwelling teleosts, for example, have adapted their lower jaw to cope with the strain of shoveling sand, and similarly, the jawbones of molluscivores have adapted to cope with the mechanical strain encountered when crushing food. 22 In addition, the zebrafish grow longitudinally throughout life, not unlike rodents, which also grow longitudinally throughout most of their life spans. 23 Recently, 2 zebrafish homologs of the runx2 gene have been identified that show expression in developing skeletal elements. 24 This will provide a valuable marker for future studies to examine the molecular mechanisms underlying the anabolic effects observed in our model. However, there are 2 notable examples in which zebrafish bones are thought to vary from those of rodents. First, the initial ossification events in the axial skeleton appear at late larval stages, from 7 to 9 dpf onwards, and these are initially through an acellular rather than an endochondral mechanism. 7 Evidence also suggests that the bone formation in the axial skeleton is inhibited rather than induced by BMP2. 5 Indeed, mutation of the zebrafish chordin gene results in defects in the axial but not craniofacial skeleton, 6 suggesting that there are regional differences in the response of the zebrafish skeleton to BMP. For these reasons, our assay focused on the effects of agents on the craniofacial skeleton because the ossification processes in this region may be more similar to those observed in mammals. A further caveat to this model system is the degree of bone remodeling that occurs during the larval period. It has previously been reported that osteoclasts can only be detected at 20 dpf and not younger. 21 However, by using an antibody rather than an enzymatic detection method, we have demonstrated the presence of osteoclasts from as early as 5 dpf (A. Fleming, unpublished data). Osteoblasts and osteocytes are also seen in larval zebrafish bone. 7 Hence, larval zebrafish bones contain the necessary cells for both bone formation and resorption activity, although modeling activity (longitudinal skeletal growth) is likely to exceed that of remodeling activity. Although the present study and existing literature suggest that zebrafish are a promising new model for bonestudying biology, additional studies will be necessary to clarify the extent to which zebrafish skeletal physiology resembles that of rodents and humans.
High-Throughput Screening for Bone Anabolic Therapies
Zebrafish have the capacity to measurably increase mineralized bone within days
As the larval zebrafish can be reared in as little as 50 µL of fluid, only tiny amounts of compound are necessary for screening. Moreover, the fish are DMSO tolerant and readily absorb chemicals and proteins such as PTH. Absorption occurs across their skin, because scales do not develop until several weeks of age, and from their gut, as they swallow from 3 dpf. The fact that a whole population of fish can be treated at the same time ensures equal administration across the entire test sample. We have demonstrated that it is possible to identify increases in bone mineralization above normal in a short period of time. As a result, a very powerful assay has been developed that can be used for the identification of new therapeutic agents as well as the dissection of pathways through standard genetic means. 3
Beneficial effects of vitamin D analogs in zebrafish
We hypothesized that zebrafish would respond similarly to the administration of vitamin D as mammals. We have shown that both vitamin D 3 and its hydroxylated forms induce anabolic effects in zebrafish and thus show that our system can be used to assay for vi- D tamin D analogs. By rearing in a calcium-free environment, it should be possible to differentiate the effects of vitamin D on gut calcium absorption from direct bone effects. Furthermore, fluorescent calcium indicators can be used in vivo, to determine whether agents cause hypercalcemia, a problematic side effect of vitamin D and its analogs. 25 Although the source of mineral ions in fish is derived largely from the aquatic environment rather than food, the teleost skeleton still plays a role in calcium homeostasis. However, it is thought that calcitonin and stanniocalcin are the major factors in maintaining calcium homeostasis in fish. 25 Therefore, the mechanism by which vitamin D analogs produce their anabolic effect in zebrafish therefore remains to be elucidated.
The role of PTH in the zebrafish skeleton
Studies on the action of PTH on bone mass have produced conflicting results. 26 It has been demonstrated that PTH has an anabolic or OP-rescuing effect when given as a single high dose but has a catabolic effect when given at a lower dose for a longer duration. 19, 20 Clinically, once-daily administration of PTH stimulates new bone formation, but continuous exposure has been likened to hyperparathyroidism, stimulating bone resorption more than formation. 27 Examination of iliac crest biopsy samples from patients treated with teriparatide revealed anabolic effects on cortical bone and increased trabecular connectivity. 28, 29 We have examined the role of PTH in our model by both intermittent and continuous exposures. A catabolic effect was observed at all doses when PTH was administered continuously. However, when administered for 1 to 2 h and then removed from the medium, we observe an anabolic effect at both 10 and 30 ng/mL. The magnitude of increase in mineralized area observed with intermittent PTH treatment was less than that which has been described in rats; however, several studies have clarified that PTH skeletal efficacy in rats occurs far in excess of what is observed clinically in humans. [30] [31] [32] [33] [34] We would suggest that the percent increase in mineral-ized area and IOD are more similar to the reported PTH efficacy in osteoporotic women.
Although the anabolic changes we observed with intermittent PTH were apparent by visual inspection, 2 different methods of image analysis revealed that the quantification of such changes must be interpreted with care. Our results demonstrate that the mineralized area gives the most robust readout of anabolic changes, whereas optical density measurements are most informative for studying bone loss. This will be an important consideration if one were to develop a similar model to screen for antiresorptive agents following bone loss. Together, these data show that PTH has effects on the growing zebrafish skeleton, not unlike the catabolic and anabolic skeletal effects described previously for continuous and intermittent PTH treatments in rats and primates. 19, 20 However, not all of the effects may be identical, as intermittent PTH did not significantly enhance longitudinal growth, as has been observed for the growing rat skeleton. 19, 20 Zebrafish have homologs to the human PTH/PTHrP receptor (PTH1R) and PTH-2 receptor (PTH2R), as well as an additional receptor (PTH3R), not described in mammals, with high homology to the PTH1R. 35 Studies have demonstrated that these receptors can bind recombinant human PTH with high affinity. 35, 36 The role of such receptors was unclear because it is known that teleosts do not have a parathyroid gland. Recently, however, 2 zebrafish PTH-like molecules have been identified that can bind and activate the human PTH1R. 14 Expression of these PTH-like genes during embryogenesis, however, does not localize to any structure that resembles a parathyroid gland equivalent, but expression is instead localized to the lateral line. Hence, the endogenous role of PTH in teleosts remains to be elucidated. 13
The potential of statins as bone anabolic agents
Positive anabolic effects were reported for statins in a calvarial bone assay in 1999, and much work has focused since on their efficacy. 37 Given their excellent tolerability and widespread use, statins may have potential as an important new anabolic therapy. Unfortunately, clinical studies have been inconclusive, suggesting that any anabolic effect seen is small. 38 We failed to see any anabolic effect with statins, a finding that is in agreement with much of the clinical data. The lack of effect is not due to a failure of absorption or lack of activity because other studies have demonstrated the efficacy of such compounds in studying HMG-CoA reductase activity in cholesterol processing and embryogenesis in zebrafish at similar concentrations to those used in the present study. 39, 40 In conclusion, we have demonstrated that larval zebrafish provide a valid assay system for bone anabolism, with similar effects to mammals being seen following administration of vitamin D 3 analogs and PTH. The full potential of this system will not be apparent until the false positive and false negative rate when moving forward into rodents has been established; but given the speed and sensitivity of the assay system, ethical preference, and pharmacological and genetic tractability, this system offers a powerful additional tool for the identification of bone anabolic agents.
